Dupilumab in Atopic Dermatitis: Rationale, Latest Evidence and Place in Therapy

Therapeutic Advances in Chronic Disease - United States
doi 10.1177/2040622318773686
Full Text
Abstract

Available in full text

Categories
Medicine
Date
Authors
Publisher

SAGE Publications

Related search

535 New Regional Dermatoses During Dupilumab Therapy for Atopic Dermatitis

Journal of Investigative Dermatology
BiochemistryDermatologyCell BiologyMolecular Biology
2019English

Dupilumab for the Treatment of Atopic Dermatitis

Prescriber
Pharmacology
2018English

Alopecia Areata After Dupilumab for Atopic Dermatitis

JAAD Case Reports
Dermatology
2018English

Dupilumab-Induced Phenotype Switching From Atopic Dermatitis to Psoriasis

JAAD Case Reports
Dermatology
2020English

Tildrakizumab in the Treatment of Psoriasis: Latest Evidence and Place in Therapy

Therapeutic Advances in Chronic Disease
Medicine
2019English

Combination Therapy With BRAF and MEK Inhibitors for Melanoma: Latest Evidence and Place in Therapy

Therapeutic Advances in Medical Oncology
Oncology
2015English

Real‐world Use of Dupilumab for 53 Patients With Atopic Dermatitis in Japan

Journal of Cutaneous Immunology and Allergy
2020English

Group 2 Innate Lymphoid Cells in Patients With Severe Atopic Dermatitis on Dupilumab

Journal of Allergy and Clinical Immunology
AllergyImmunology
2019English

Remission of Alopecia Universalis in a Patient With Atopic Dermatitis Treated With Dupilumab

JAAD Case Reports
Dermatology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy